Menu
Search
|

Menu

Close
X

Syneos Health Inc SYNH.OQ (NASDAQ Stock Exchange Global Select Market)

45.76 USD
-0.30 (-0.65%)
As of 4:00 PM EDT
chart
Previous Close 46.06
Open 45.40
Volume 203,909
3m Avg Volume 173,318
Today’s High 46.51
Today’s Low 44.09
52 Week High 59.40
52 Week Low 31.10
Shares Outstanding (mil) 102.88
Market Capitalization (mil) 4,892.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.21 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY18
2,130
FY17
2,672
FY16
1,611
FY15
1,399
EPS (USD)
FY18
-0.105
FY17
-0.491
FY16
2.028
FY15
1.964
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
1.21
6.55
Price to Book (MRQ)
vs sector
1.73
4.00
Price to Cash Flow (TTM)
vs sector
23.89
21.51
Total Debt to Equity (MRQ)
vs sector
102.78
14.15
LT Debt to Equity (MRQ)
vs sector
100.92
11.31
Return on Investment (TTM)
vs sector
-2.40
12.83
Return on Equity (TTM)
vs sector
-5.01
14.95

EXECUTIVE LEADERSHIP

Michael Bell
Executive Chairman of the Board, Since 2017
Salary: $850,000.00
Bonus: --
Alistair Macdonald
Chief Executive Officer, Director, Since 2016
Salary: $852,703.00
Bonus: --
Jason Meggs
Chief Financial Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
Lisa van Capelle
Chief Human Resource Officer, Since 2018
Salary: --
Bonus: --
Purvesh Patel
Executive Vice President, Interim General Counsel and Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3201 Beechleaf Ct Ste 600
RALEIGH   NC   27604-1500

Phone: +1919.8769300

Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

SPONSORED STORIES